Asia Pacific Next Generation Sequencing (NGS) Market  By Type (Products (Instruments & Software, Consumables (Reagents & kits) and Services (Sequencing Services and Data Analysis Services)), By Technology (Whole Targeted Re-sequencing, Whole Genome Sequencing, Transcriptome (RNA-Seq), Whole Exome Sequencing, De Novo Sequencing, ChiP Sequencing, Methylation Sequencing, and Others), By Application (Diagnostics, Drug Discovery & Development, Biomarker Discovery, Agriculture & Animal Health Research, and Personalised Medicine) By End User (Academic Institutes & Research Centers, Hospital/Clinical Laboratories, Biotech/Pharmaceuticals Companies, and Others), and Country

 

The asia-pacific next generation sequencing market size valued USD 570 million in 2020 and expected to grow at a CAGR of 24.0% during the forecast period 2017-2027. Massively parallel sequencing (MPS) is another name for next-generation sequencing (NGS) . This word refers to a DNA sequencing method that has benefited biotech, forensic biology, medical diagnosis, biological systematics, and virology. NGS has evolved as a method for completing clinical research, basic science, and applied science. In comparison to the earlier Sanger sequencing method, next-generation sequencing allows a full human genome to be sequenced in a fraction of the time. This report presents Next Generation Sequencing (NGS) market dynamics elaborately to identify the current market trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, Next Generation Sequencing (NGS) market report includes the competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed Next Generation Sequencing (NGS) market to better equip clients with possible investment opportunities across the regions (Country Investment Hot-Spots) and market unmet needs.